Abstract 76P
Background
The study is aimed to identify perception and satisfaction of cancer patients who participate in clinical trials.
Methods
The participants of the study were 110 cancer patients who participated in clinical trials over 2nd cycle at a tertiary hospital, Seoul, South Korea. The instruments used were the perception and satisfaction of cancer patients in clinical trials developed after evaluating content validity index. The collected data were analyzed with descriptive statistics, independent t-test, one-way ANOVA and Pearson Correlation Coefficients.
Results
The mean perception of clinical trial of patients was 3.97±0.46 out of 5.0. The mean satisfaction of clinical trial of patients was 4.10±0.55 out of 5.0. The perception of cancer patients in clinical trials was significantly difference according to types of cancers (F = 2.88, p=.018), participation period (F = 3.13, p=.029) and subjective understanding of the clinical trial (t = 2.65, p=.015). Satisfaction of cancer patients showed significant difference according to religion (t = 2.32, p=.023), participation period (F = 3.39, p=.021), motive to participate (F = 3.18, p=.010) and decision maker of participation (t = 2.60, p =.025). Perception and satisfaction of cancer patients in clinical trials were positively correlated (r=.66, p<.001).
Conclusions
The results of study can be used as a basis for education program for cancer patients participating in clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract